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Graphical abstract 
 
 
Abstract 
Gout is a paradigm of acute, self-limiting inflammation caused by the deposition of monosodium 
urate (MSU) crystals within intra-and/or peri-articular areas, which leads to excruciating pain, joint 
swelling and stiffness. The infiltration of leukocytes drives the inflammatory response and remains 
an attractive target for therapeutic intervention. In this context, emerging evidence support the view 
that systemic differentiation of Th17 cells and their in-situ infiltration as one of the potential 
mechanisms by which these cells, and their main product IL-17, causes damage to the target tissues. 
To test if IL-17 was having a detrimental role in gouty onset and progression we targeted this 
cytokine, using a neutralizing antibody strategy, in an experimental model of gout. 
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Joint inflammation was induced in CD-1 mice by the intra-articular (i.a.) administration of MSU 
crystals (200 μg/20 µl). Animals from IL-17Ab-treated groups received 1, 3 and 10 µg (i.a.) in 20 
µl of neutralizing antibody 30 minutes after MSU crystals administration. Thereafter, joints were 
scored macroscopically, and knee joint oedema determined with a caliper. Histological analyses, 
myeloperoxidase assay and western blots analysis for COX-2/mPGEs-1/IL-17R pathway were 
conducted at the 18 h time-point (peak of inflammation) to evaluate leukocyte infiltration and 
activation, followed by the analysis, in situ, of ~40 pro/anti-inflammatory cytokines and 
chemokines. Flow cytometry was also used to evaluate the modulation of infiltrated inflammatory 
monocytes and systemic Th17 and Treg profile. Treatment with IL-17Ab revealed a dose-dependent 
reduction of joint inflammation scores with maximal inhibition at 10 μg/20 µl. The neutralizing 
antibody was also able to significantly reduce leukocyte infiltration and MPO activity as well the 
expression of JE, IL-1α, IL-1β, IL-16, IL-17, C5a, BLC and, with a less extent IP-10, Rantes, KC, 
TIMP-1, SDF-1 and metalloproteinases in inflamed tissues. Biochemical analysis also revealed that 
IL-17Ab treatment modulated COX-2/mPGEs-1 pathway (and related PGE2 production) without 
interfering with IL-17R expression.  
Furthermore, flow cytometry analysis highlighted a selective modulation of infiltrating 
inflammatory monocytes (B220-/GR1hi-F480hi/CD115+) and circulating Th17, but not Treg, cells 
after IL-17Ab treatment.  
Collectively the results of this study report for the first time, that i.a. injection of MSU crystals 
stimulates in vivo production of Th17 cells and Th17-related inflammatory cyto-chemokines. In 
addition, we have demonstrated that the administration of a neutralizing antibody against IL-17 
attenuates joint symptoms, swelling and leukocytes infiltration to the inflamed tissue, possibly 
providing a new strategy for the treatment of gouty inflammation and/or arthritis. 
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Abbreviations: Ab, Antibody; BLC, B lymphocyte chemoattractant; BSA, bovine serum albumin; 
Cyto-chemokines, cytokines and chemokines; COX, cyclogeneses; C5a, complement component 
5a; DMSO, dimethylsulfoxide; EDTA, ethylenediamine tetraacetic acid; EGTA, ethylene glycol 
tetraacetic acid; FACS, fluorescence activated cell sorting; FBS, fetal bovine aGA, gouty arthritis; 
H&E, haematoxylin and eosin; i.a, intra-articular; IL-, interleukin-; IP-10, inducible protein 10; KC, 
keratinocyte chemoattractant; MCP-1, monocyte chemoattractant protein-1; mPGEs, microsomal 
prostaglandin synthetase; MHC, major histocompatibility complex; MIP-, macrophage 
inflammatory proteins-; MPO, myeloperoxidase; MSU, monosodium urate; PBS, phosphate 
buffered saline; PGE2, prostaglandin E2; PMSF, phenylmethansulfonyl fluoride; RA, rheumatoid 
arthritis; RANTES, regulated on activation normal T expressed and secreted; RT, room 
temperature; SDF-1, stromal cell-derived factor 1; TIMP-1, metallopeptidase inhibitor-1; TNF-α, 
tumor necrosis factor alfa; TREM-1, triggering receptor expressed on myeloid cells-1. 
Keywords: Gout; IL-17A; Inflammation; Monosodium urate crystal; Neutralizing antibody. 
 
Chemical compounds studied in this article: Ethanol (PubChem CID:702); PGE2 (PubChem 
CID:5280360); Phosphate-buffered saline (PubChem CID: 24978514); Sodium chloride (PubChem 
CID:5234); Sodium urate (PubChem CID: 23697816). 
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1. Introduction  
Gout is a paradigm of acute, self-limiting inflammation caused by increased blood uric acid levels 
and damaging effects of monosodium urate (MSU) crystals accumulation within intra-and/or peri-
articular areas [1]. Under long-standing hyperuricemia, MSU crystals deposits, usually associated 
with tophi, further induce chronic inflammatory response that may lead to joint structure damage, 
often referred to as gouty arthritis (GA) or chronic gout [2]. 
During the progression of the inflammatory response and gouty attack, MSU crystals induce a 
significant leukocyte infiltration into the joint cavity [3].  This early pathologic hallmark is mainly 
characterized by neutrophil influx into the joint fluid followed by monocytes/macrophages that, in 
turn, phagocytose MSU crystals resulting in membranolytic and inflammasome activation [4,5], 
generation of oxygen derived free radicals, release of lysosomal enzymes, pro-inflammatory 
interleukins (mainly IL-1, IL-6 and TNF-α) and PGE2 [6,7].  
PGs and leukotrienes are powerful bioactive lipid mediators involved in numerous homeostatic 
functions but also in the onset of inflammation [8]. Their biosynthesis is initialized by COXs and 
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then finalised PGE2 synthases (by the inducible isoform mPGEs-1) that convert PGH2 [9] to PGE2 
[10,11]. Recently, several biochemical and pharmacological studies demonstrated a molecular 
interaction between COX and PGEs isoenzymes [12,13] resulting in preferential functional 
coupling activity of COX-2/mPGEs-1/PGE2, which triggers the inflammatory response associated 
with conditions such as gout [14,15,16,17]. However, it is still unclear how this process is being 
regulated and which molecular mechanisms are detrimental for gouty inflammation onset [18,19]. 
In this context, emerging evidences support the view that systemic differentiation and maturation of 
Th17 cells and local recruitment as one of the potential mechanisms by which these cells cause 
damage to target tissues. Liu et al. [20] reported significantly elevated levels of IL-17 in the serum 
of GA patients early in the onset of symptoms of gout and decrease gradually as symptoms 
diminish. Moreover, recent work highlighted that, although the genetic variants in IL-17 do not 
appear to be involved in the development of gout [21], systemic Th17/Treg imbalance changes over 
time during the development of acute gouty arthritis and a decrease in ratio, favouring Th17 cells is 
consistent with inflammation development in the joints [22]. 
We and others have also highlighted the importance of  IL-17 (and IL-17 related cytokines), 
[23,24,25] in sustaining the release of multiple mediators such as IL-1, IL-6, IL-8, PGE2 and MCP-
1 (also known as JE) by a wide variety of cells involved both directly and indirectly, on GA physio-
pathology, including fibroblasts, endothelial cells, neutrophils and inflammatory monocytes. 
[26,27,28]. 
Collectively these findings suggest a detrimental role for IL-17 in GA onset and progression and 
helped us to formulate the hypothesis that targeting IL-17, by a neutralizing antibody strategy, could 
provide a novel treatment strategy to target gouty inflammation and/or arthritis. 
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2. Materials and methods 
2.1 Reagents 
Flow cytometry fixation and permeabilization buffer Kit I, PGE2 Elisa kit, proteome profiler mouse 
cytokine array Kit, recombinant mouse IL-17 (also known as IL-17A) neutralizing antibody (IL-
17Ab, monoclonal rat IgG2A, clone 50104) and its related isotype control (IgG2A, clone 54447) were 
purchased from R&D System (Milan, Italy). Collagenase (Type VIII), fetal bovine serum (FBS), 
hyaluronidase, monosodium urate crystals, E-Toxate™ reagent from Limulus Polyphemus and 
RPMI-1640 cell medium were purchased from Sigma‐ Aldrich Co. (Milan, Italy) whereas FACS 
buffer and conjugated antibodies from BioLegend (London, UK). Ficoll-Paque Plus (endotoxin 
tested, ≤ 0.12 EU/ml) was obtained from GE Healthcare Bio-Sciences AB (Uppsala, Sweden). For 
western blot analysis, the primary antibodies were obtained from Elabioscience (Milan, Italy) 
whereas the HRP-conjugated IgG secondary antibodies from Dako (Copenhagen, Denmark). Unless 
otherwise stated, all the other reagents were from BioCell (Milan, Italy).  
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2.2 Animals 
All animal care and experimental procedures were carried out in compliance with the international 
and national law and policies and approved by Italian Ministry of Health. Animal studies were 
reported in compliance with the ARRIVE guidelines and with the recommendations made by EU 
Directive 2010/63/EU for animal experiments and the Basel declaration including the 3Rs concept 
[29,30]. CD‐ 1 male mice (10–14 weeks of age, 25–30 g of weight) were purchased from Charles 
River (Milan, Italy) and kept in an animal care facility under controlled temperature, humidity, and 
on a 12 hr:12 hr light:dark cycle, with ad libitum access to water and standard laboratory chow diet. 
All procedures were carried out to minimize the number of animals used (n=6 per group) and their 
suffering. 
2.3 Preparation of MSU crystals 
The MSU crystals were prepared as previously described [31]. Briefly, 800 mg of MSU were 
dissolved in 155 ml of boiling milli-Q water containing 5 ml of NaOH, and after the pH was 
adjusted to 7.2, the solution was cooled gradually by stirring at room temperature and crystals 
collected after centrifugation at 3.000 g for 5 min at 4ºC. The obtained crystals were washed twice 
with 100% ethanol, dried, autoclaved (180ºC for 2 hours), and weighed under sterile conditions. 
Crystals were resuspended in PBS by sonication and stored in a sterile environment until use. MSU 
crystals were confirmed as endotoxin-free by a commercial test kit of limulus polyphemus lysate 
assay (<0.01 EU/10 mg). 
 
2.4 Induction of MSU-induced knee joint inflammation  
Joint inflammation was induced by the intra-articular (i.a.) administration of MSU crystals (200 
μg/20 µl) into the right knee joint of mice under isoflurane anaesthesia. Control animals received an 
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i.a. injection of PBS (20 μl) or 20 μl of IL-17Ab isotype control. Animals from IL-17Ab-treated 
groups received 1, 3 and 10 µg (i.a.) in 20 µl of neutralizing antibody 30 minutes after MSU 
crystals administration.  
 
2.5 Joint scoring and evaluation 
In a preliminary experiment finalized to evaluate the dose-responsive effect of IL-17Ab, the joints 
from different experimental conditions were scored macroscopically on a scale from 0 to 3, where 0 
= no inflammation, 1 = mild inflammation, 2 = moderate inflammation, and 3 = severe 
inflammation, in increments of 0.25. A score of 0.25 was given when the first signs of swelling and 
redness were present. Joint swelling scoring was performed by two authors without knowledge of 
the experimental groups [32]. After macroscopic scoring, knee joint oedema was determined with a 
caliper (Mitutoyo) before (zero time), and after the i.a. injection with MSU crystals or MSU crystals 
plus IL-17Ab at the times indicated. Knee joint oedema was determined for each mouse by 
subtracting the initial paw value to the paw value measured at each time point and presented as Δ 
mm/joint [31]. 
 
2.6 Histology 
Histological analysis was conducted at the 18 h time-point. Joints were trimmed, placed in 
decalcifying solution (EDTA 0.1 mM in PBS) for 14 days and then embedded in paraffin. Sections 
(5 μm) were deparaffinized with xylene and stained with haematoxylin and eosin (H&E) as 
previously described [23] for conventional morphological evaluation. A dimension used for the 
analysis of the slices was 569 x 633 pixels and magnification ×20. In all cases, a minimum ≥3 
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sections per animal were evaluated. Phase-contrast digital images were taken using the Image Pro 
image analysis software package. 
 
2.7 Myeloperoxidase assay 
Leukocyte myeloperoxidase (MPO) activity was assessed by measuring the H2O2‐ dependet 
oxidation of 3,3′,5,5′‐ tetramethylbenzidine as previously reported [23]. Tissues (knee joint) were 
homogenized for 35 s in a solution composed of hexadecyltrimethylammonium bromide (0.5% w/v) 
in 50 mM sodium phosphate buffer pH 5.4. After homogenization, samples were centrifuged (4000 
g) for 20 min and the supernatant used for the assay. Aliquots of 20 μl were incubated with 160 μl 
of 3,3′,5,5′‐ tetramethylbenzidineand 20 μl of H2O2 (in 80 mM phosphate buffer, pH 5.4) in 
96‐ well plates. Plates were incubated for 5 min at room temperature, and OD was read at 620 nm 
using a plate-reader (Biorad, Italy). Assay were performed in duplicates and normalized for protein 
content. 
 
2.8 Western blot analysis  
Whole knee joints homogenates (35 μg of protein) were subjected to SDS-PAGE (12% gel) using 
standard protocols as previously described [33]. The proteins were transferred to PVDF membranes 
in the transfer buffer [25 mM Tris–HCl (pH 7.4) containing 192 mM glycine and 20% v/v 
methanol] at 400 mA for 2 h. The membranes were saturated by incubation for 2 h with non-fat dry 
milk (5% wt/v) in PBS supplemented with 0.1% (v/v) Tween 20 (PBS-T) for 2 h at RT and then 
incubated with 1:2000 dilution of primary antibodies over-night at 4○C as such as mouse 
monoclonal anti-COX-2 (E-AB-27666), rabbit polyclonal anti-mPGEs-1 (E-AB-32563), rabbit 
polyclonal anti-IL-17R (E-AB-63080) and mouse monoclonal anti-actin (E-AB-20094) and then 
AC
CE
PT
ED
 M
AN
US
CR
IPT
11 
 
washed 3 times with PBS-T. Blots were then incubated with a 1:3000 dilution of related horseradish 
peroxidase-conjugated secondary antibody for 2 h at RT and finally washed 3 times with PBS-T. 
Protein bands were detected by using the enhanced chemiluminescence (ECL) detection kit and 
Image Quant 400 GE Healthcare software (GE Healthcare, Italy). Protein bands were quantified 
using GS 800 imaging densitometer software (Biorad, Italy) and normalized with respective actin.  
 
2.9 Isolation and characterization of joint-infiltrating cells 
According to the protocol described by Akitsu and colleagues [34] ankle joints were cut out and 
digested with hyaluronidase (2.4 mg ml−1) and collagenase (1 mg ml−1) in RPMI 1640 plus 10% 
FBS for 1 h at 37 °C. The cells were filtered through a cell strainer with a 70-μm nylon mesh 
(Becton Dickinson, Franklin Lakes, NJ, USA) and washed with RPMI 1640 plus 10% FBS. 
Thereafter, collected cells were washed in PBS for total cell count before flow cytometry analysis. 
 
2.10 Cytokines and Chemokines Protein Array 
All mice were killed at indicated time-point and knee joint immediately removed and collected into 
a 2 ml tube for an immediate preservation in liquid nitrogen and a successive storage at −80°C. The 
isolated tissues were homogenized in ice‐ chilled Tris–HCl buffer (20 mM, pH 7.4) containing 1 
mM EDTA, 1 mM EGTA, 1 mM PMSF, 1 mM sodium orthovanadate, and one protease inhibitor 
tablet per 50 ml of buffer. Protein concentration was determined by the BioRad protein assay kit 
(BioRad, Italy). Equal volumes (1.5 ml) of the pulled homogenates were then incubated with the 
precoated proteome profiler array membranes according to the manufacturer's instructions. Dot 
plots were detected by using the enhanced chemiluminescence detection kit and Image Quant 400 
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GE Healthcare software (GE Healthcare, Italy) and successively quantified using GS 800 imaging 
densitometer software (Biorad, Italy). 
 
2.11 ELISA assay  
Enzyme-linked immunosorbent assay for PGE2 was carried out on whole knee joints homogenates. 
Briefly, 100 µl of tissue supernatants, diluted standards, quality controls and dilution buffer (blank) 
were added to a pre-coated plate with monoclonal anti-PGE2 for 2 h. After washing, 100 µl of biotin 
labeled antibody was added for 1 h. The plate was washed and 100 µl of streptavidin-HRP 
conjugate was added and the plate was incubated for a further 30 min period in the dark. The 
addition of 100 µl of the substrate and stop solution represented the last steps before the reading of 
absorbance (measured at 450 nm) on a microplate reader. Antigen levels in the samples were 
determined using a standard curve of PGE2 and expressed as pg ml
-1. 
 
2.12 Flow cytometry 
Lymphocytes were isolated from whole blood (collected by intracardiac puncture) by Ficoll-Paque 
Plus gradient method were washed in FACS buffer (PBS containing 1% BSA and 0.02% NaN2) and 
directly stained with the following conjugated antibodies (all from BioLegend, London, UK): CD4 
(1:200; clone GK1.5), CD8 (1:200; clone 5H10-1), CD25 (1:200; clone 3C7) for 60 minutes at 4ºC. 
After washing, cells were fixated, permeabilized, and stained intracellularly with IL-17A (1:200; 
clone TC11-18H10.1) and Foxp3 antibody (1:200: clone MF-14). Th17 and Treg population were 
defined as CD4+IL-17+ and CD4+CD25+Foxp3+ cells respectively. For the characterization of joint-
infiltrating cells we adopted a similar procedure followed by the incubation with GR1 (1:300; clone 
RB6-8C5), F480 (1:300; clone BM8), B220 (1:200; clone RA3-6B2), CD115 (1:200; clone AFS98) 
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for 60 minutes at 4ºC. T cell, neutrophils, macrophage and resident/inflammatory monocytes were 
defined according to the flow cytometry procedure previously described [25,35]. At least 1x104 
cells were analysed per sample, and determination of positive and negative populations was 
performed based on the staining attained with irrelevant IgG isotypes. Flow cytometry was 
performed on BriCyte E6 flow cytometer (Mindray Bio-Medical Electronics, Nanshan, China) 
using MRFlow and FlowJo software operation.  
 
2.13 Data and statistical analysis 
The data and statistical analysis in this study comply with the international recommendations on 
experimental design and analysis in pharmacology [36] and data sharing and presentation in 
preclinical pharmacology [37,38]. The results obtained were expressed as the mean ± SD. Statistical 
analysis were performed by using one‐ way ANOVA followed by Bonferroni or Dunnett's 
post‐ test, when comparing more than two groups. GraphPad Prism 7.0 software (San Diego, CA, 
USA) was used for analysis. Data were considered statistically significant when a value of P≤0.05 
was achieved.  
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3. Results 
3.1 Neutralization of IL-17 reduces the severity of MSU-induced gouty inflammation 
I.a. injection of MSU crystals into mouse knee joints was used to mimic the etiologic cause of 
human gouty inflammation [39]. MSU crystals injection produced an intense and reproducible joint 
inflammatory score (that peaked between 18 and 24h) that was dose-dependently attenuated by the 
administration of IL-17Ab (1-10 µg/20µl), with a maximum inhibition rate observed at dose of 
10µg. A significant, but lesser, effect was observed when IL-17Ab was administrated at dose of 
3µg, then abrogated at dose of 1µg (Fig. 1A). Administration of IL-17Ab isotype control (IgG2A) 
had no significant effects on clinical scores (data not shown).  
Based on these results, we evaluated joint swelling in a time course experiment with the most active 
dose of IL-17Ab (10µg). As shown in Fig. 1B, neutralization of IL-17 remarkably decreased joint 
swelling between 18 and 24h. All inflammatory parameters subsided by 24–48h after MSU crystals 
injection. 
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Fig. 1. IL-17Ab modulates MSU crystals-induced gouty inflammation and oedema. Mice were 
treated with IL-17Ab (1.0, 3.0 and 10µg/20µl) or IL-17Ab vehicle (20µl PBS) 30 min after to intra-
articular stimulation with MSU crystals (200μg/20μl) in the right knee joint. (A) Joint inflammation 
score (0-3 in increments of 0.25) was evaluated at 4, 18, 24 and 48 h and (B) joint inflammation 
oedema was evaluated at 1,2,3,4,5,6,18, 24 and 48 h after the stimulus with MSU. Data (expressed 
as joint inflammation score and Δ increase of knee joint mm) are presented as means ± SD of n=6 
mice per group. Statistical analysis was conducted by one-way ANOVA followed by Bonferroni’s 
multiple comparisons. #P≤0.05, ##P≤0.01, ###P≤0.005 vs Ctrl group; *P≤0.05, **p≤0.01 vs MSU 
group. 
 
3.2 IL-17Ab ameliorates MSU-induced leukocytes recruitment and activation to the knee 
joints 
Leukocyte recruitment into the knee joint is a hallmark of gout inflammation and arthritis pathology 
[40,41]. Thus, based on previous results, we selected the most active doses (10μg) of IL-17Ab to 
test the modulation of leukocyte recruitment and activation. The histopathological (H&E) findings 
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(Fig. 2A, 2C) show that IL-17Ab reduced inflammatory cell recruitment to the knee joint (Fig. 2C) 
compared to MSU crystals-treated mice (Fig. 2B), suggesting a reduction in synovitis. We also 
observed a significant reduction in MPO activity (a surrogate marker for granulocyte infiltration) in 
the knee joints of IL-17Ab-treated mice compared to MSU crystals group alone (Fig. 2D).  
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In line with these observations, it has been reported that in several tissues and different cell types 
including leukocytes, fibroblasts, osteoblasts and chondrocytes, mPGEs-1 expression is enhanced 
by a variety of inflammatory factors including LPS, IL‐ 1β, TNF‐ α, and IL-17, the latter of which 
was targeted in this study [42,43,44]. Western blot analysis performed on whole knee joint 
homogenates showed that COX-2 (Fig. 3A) and mPGEs-1 (Fig. 3B) were up-regulated during MSU 
crystals condition and were both significantly decreased after IL-17Ab treatment (Fig. 3E, 3F 
respectively). Moreover, we observed that IL-17 receptor (IL-17R) expression (increased in MSU-
treated animals compared to Ctrl group) was not influenced after IL-17Ab administration (Fig. 3C, 
3G). Notably, we observed a strong reduction of soluble PGE2 levels in IL-17Ab-treated group 
compare to MSU-treated animals (Fig. 3H).  
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Fig. 2. IL-17Ab treatment moderates leukocyte infiltration in the mouse knee joint. Mice were 
treated with IL-17Ab (10µg/20µl) or IL-17Ab vehicle (20µl PBS) 30 min after to intra-articular 
stimulation with MSU crystals (200μg/20μl) in the right knee joint. Thereafter, at 18h time-point 
knee joint tissues were stained for haematoxylin-eosin (A-C) and tested for myeloperoxidase 
activity (D). H&E pictures are representative of three independent experiments with similar results. 
Data of MPO activity (expressed as Units for mg of tissue) are presented as means ± SD of n=6 
mice per group. Statistical analysis was conducted by one-way ANOVA followed by Bonferroni’s 
multiple comparisons. ###P≤0.005 vs Ctrl group; **p≤0.01 vs MSU group.  
 
 
Fig. 3. IL-17Ab modulates COX-2 and mPGEs-1 expression in MSU crystals-induced gouty 
inflammation. Whole knee joints homogenates from Ctrl, MSU and MSU + IL-17Ab group were 
analysed by western blot for COX-2 (A), mPGEs-1 (B), IL-17R (C) and their actin expression with 
related cumulative densitometric values (E-G). WB pictures are representative of three separate 
experiments with similar results. Thereafter, whole homogenates from different experimental 
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conditions were assayed by ELISA for PGE2 levels (E). Data of ELISA assay (expressed as pg/ml) 
are presented as means ± SD of n=6 mice per group. Statistical analysis was conducted by one-way 
ANOVA followed by Bonferroni’s multiple comparisons. ##P≤0.01 vs Ctrl group; *p≤0.05 vs MSU 
group.  
 
3.3 Injection of IL-17Ab into the knee joints reduces the recruitment of inflammatory 
monocytes 
To investigate and compare the phenotype of inflammatory leukocytes recruited by MSU injection 
we stained cells with an anti-B220, anti-CD115, anti-F480, anti-GR1 antibodies and analysed by 
flow cytometry. Specifically, to identify potential differences in monocyte subpopulations, we first 
gated on the B220- population (Gate R1, Figure 4A, 4D and 4G) and then determined GR1 and 
F480 expression (Fig. 4B, 4E, 4H). Double positive population for these markers (Gate R2) was 
then further interrogated for CD115 (Fig. 4C, 4F, 4I) as their expression level is commonly 
correlated with the degree of maturation of inflammatory monocytes [45,46]. Our results show that 
in MSU-injected mice, the majority of cells recovered were B220-/GR1hi-F480hi/CD115+ 
(88.30±2.48 compared to 71.70±2.57 of Ctrl) with a significant lower expression in IL-17Ab-treatd 
group (75.30±2.29) (Fig. 4J). These values were strengthened by an irrelevant percentage of 
positive cells found in the staining for the isotype control antibodies (data not shown).  
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Fig. 4. Flow cytometry strategy applied to identify the modulation of inflammatory monocytes 
in MSU and MSU + IL-17Ab-tretaed groups. Ankle joints were digested, and single cell 
suspensions were obtained. Cells were washed and stained with the following panel of antibodies; 
anti-B220, anti-CD115, anti-F480, anti-GR1. Cells negative for B220 (R1, A, D, G) were plotted 
for GR1-F480 (B, E, H) in order to get a double positive population (R2) followed by further 
characterization based on CD115 (C, F, I). The numbers in the dot plots indicated the percentage of 
positively stained cells after gating strategy whereas histograms values (J) indicated the percentage 
of CD115 positive stained cells. FACS plots are representative of three independent experiments 
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with similar results. Data are presented as means ± SD of n=6 mice per group. Statistical analysis 
was conducted by one-way ANOVA followed by Bonferroni’s multiple comparisons. ##P≤0.01 vs 
Ctrl group; **p≤0.01 vs MSU group. 
 
We next sought to determine the effect of IL-17Ab on MSU crystals-induced pro-inflammatory 
cyto-chemokines production (Fig. 5A) given the importance of pro-inflammatory mediators to gout 
pathology onset [47]. MSU crystals administration induced a robust increase of JE, IL-1α, IL-1β, 
IL-16, IL-17, C5a, BLC and, with a less (but still significant) extent IP-10, Rantes, KC, TIMP-1, 
SDF-1 and metalloproteinases (Fig. 5C) compared to Ctrl group (Fig. 5B). Interestingly, treatment 
with IL-17Ab (Fig. 5D) reverted this cyto-chemokines over-production next to MSU crystals-
treated mice (Fig. 5E). IL-17Ab isotype control did not alter the levels of any of the mediators 
measured (data not shown) 
 
Fig. 5. Survey of inflammatory mediators collected from mice receiving MSU and IL-17Ab 
injection in the knee joint. Inflammatory fluids obtained from homogenates knees joints were 
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assayed using a Proteome Profiler cytokine array (A) for Ctrl (B), MSU (C) and MSU + IL-17Ab 
(D) group. The bar graph (E) shows the densitometric analysis of the arrays in B–D. Bars show 
mean changes ± SD. of positive spots of three independent experiments with n=6 mice obtained as a 
Δ of increase/decrease in the INT/mm2 between MSU and Ctrl (red bar) and MSU + IL-17Ab and 
MSU (blue bar). Statistical analysis was conducted by one-way ANOVA followed by Bonferroni’s 
multiple comparisons. #P≤0.05, ##P≤0.01, ###P≤0.005 vs Ctrl group; *P≤0.05, **p≤0.01, ***p≤0.005 
vs MSU group.  
 
3.4 In situ administration of MSU and IL-17Ab influences systemic Th17 and Treg balance 
In order to clarify whether the differing inflammatory profiles observed in the knee joints were 
correlated to different systemic Th17 and Treg balance, we stained isolated lymphocytes cells with 
an anti-CD4, an accessory protein for MHC class-II antigen/T-cell receptor interaction, an anti-
CD8, a marker that identifies cytotoxic/suppressor T-cells that interact with MHC class I and then 
with an anti-CD4/IL-17 and anti-CD4/CD25/Foxp3 in order to identify Th17 and Treg population 
respectively according to previous protocols [48,49]. 
The results obtained did not reflect any significant difference in the levels of CD4+ and CD8+ cells 
in all experimental conditions (Fig. 6A, 6D). However, as shown in Fig. 6E and 6G, MSU crystals-
treated mice displayed a strong increase in the percentage of Th17+ cells (12.70±3.85) compared to 
Ctrl group (0.01±0.002) which was significantly reduced after IL-17Ab treatment (2.55±1.10). This 
systemic lymphocyte profile change (Fig. 6G) did not affect the Treg repertoire, given that we did 
not observe any significant difference in terms of CD4+CD25+Foxp3+ cells (Fig. 6F and 6H). These 
values were strengthened by irrelevant percentage of positive cells found in all the staining for the 
isotype control antibodies (data not shown).  
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Fig. 6. IL-17Ab influences Th17 and Treg ratio on peripheral blood. Lymphocytes isolated 
from whole blood by Ficoll-Paque Plus gradient method were washed, stained with CD4 (A), CD8 
(B) and CD4/IL-17 (E). Finally, CD4+ cells were plotted for CD25/Foxp3 (F) and analysed by 
FACS. Histograms values (C, D, G and H) indicated the percentage of positively stained cells in 
the different experimental conditions. FACS pictures are representative of three independent 
experiments with similar results. Data are presented as means ± SD of n=6 mice per group. 
Statistical analysis was conducted by one-way ANOVA followed by Bonferroni’s multiple 
comparisons. ##P≤0.01 vs Ctrl group; **p≤0.01 vs MSU group.  
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
24 
 
 
 
4. Discussion  
The results of this study show, for the first time, that i.a. injection of MSU crystals stimulates in 
vivo production of Th17 cells and Th17-related inflammatory cyto-chemokines. In addition, we 
have provided evidence that the administration of a neutralizing antibody against IL-17 attenuates 
joint symptoms, swelling and leukocytes infiltration/activation to the inflamed tissues, possibly 
providing a new strategy for the treatment of gouty inflammation and/or arthritis. 
Gout is characterized by the deposition of MSU crystals in joints, which is associated with the rise 
of serum urate content, leading to excruciating pain and inflammatory events [50, 51]. MSU 
crystals deposits or tophi further induce chronic inflammatory responses that may lead to joint 
damage, often referred to as gouty arthritis or chronic gout [52]. Moreover, MSU crystals can also 
cause acute, self-limited, inflammatory flares, which are likely triggered by crystal shedding from 
the cartilage surface into the joint space, where they can interact with resident cells. 
All these processes are mainly related to activated neutrophils and macrophages which are 
responsible for the release of PGE2, IL-1β, TNF-α, and, activate nociceptor neuron and thereby 
producing pain [53,54,55]. Indeed, targeting IL-1β, TNF-α or PGE2 in rheumatic diseases reduce 
neutrophil recruitment and associated pain [40]. 
Recent evidences have highlighted that serum IL-17 levels are significantly elevated in GA patients 
[20] and that systemic Th17/Treg imbalance is consistent with inflammation development in the 
joints. Accordingly, the changes of Th17/Treg ratio decrease at an earlier stage followed by an 
increase at a later stage, suggesting a photogenic role of this specific CD4+ subset in gouty onset 
and development [22]. In line with these observations, here we have demonstrated that MSU 
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crystals injection in mice induce the up-regulation of different mediators strictly correlated with 
biological activity of IL-17 and Th17 cells profile [56]. We found that MSU crystals administration 
induced the modulation of i) typical pro-inflammatory cytokines such as IL-1α, IL-1β, IL-16, IL-17 
and Trem-1, ii) different chemokines such as BLC, IP-10, JE, SDF-1 and Rantes involved in 
leukocytes recruitment and activation and iii) other activators of inflammation such as C5a, the 
chemotactic cytokines MIP-1/2 and the tissue inhibitor of metalloproteinase TIMP-1.  
In line with these observations, it has been reported that in several tissues and different cell types 
including leukocytes, fibroblasts, osteoblasts and chondrocytes mPGEs-1 expression is enhanced by 
a variety of inflammatory factors including LPS, IL‐ 1β, TNF‐ α, and IL-17, the latter of which 
was targeted in this study [42,43,44]. COX-2/mPGEs-1 is a very complex enzymatic process that 
initiate the formation of PGE2 and lengthening of the pro-inflammatory and pro-nociceptive stimuli 
[11,57]. The concept of a changeable PGs production pathway (including the modulation of both 
COX-2 and mPGEs-1) could have important implications for understanding the inflammatory 
events typical of certain illness including gouty inflammation and/or arthritis. Interestingly, we have 
demonstrated that COX-2 and mPGEs-1 were up-regulated during MSU administration and both 
decreased after IL-17Ab treatment. This finding was also confirmed by a strong reduction of PGE2 
levels observed in IL-17Ab-treated group. The selective modulation of COX-2/mPGEs-1 pathway 
was also correlated with the observation that IL-17 receptor expression (increased in MSU-treated 
animals compared to Ctrl group) was not influenced by IL-17Ab administration. All these 
biochemical changes were consistent with those observed macroscopically. Indeed, administration 
of a neutralizing monoclonal antibody against IL-17 prevented swelling of the inflamed joints 
between 18 and 24 h, but it failed to have a consistent effect at other time points of observation.  
Successively, to investigate and compare the phenotype of the inflammatory leukocytes recruited by 
MSU injection into knee joints, we first gaited on cells isolated from knee joints for B220- 
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population, followed by GR1-F480 expression to finally identify the level of CD115+, commonly 
correlated with the degree of maturation of inflammatory monocytes [45,46]. Our results show that 
in MSU-injected mice, most of the cells recovered were inflammatory monocytes with a significant 
lower expression of mentioned markers in IL-17Ab-treatd group. 
The inflammatory effects of MSU crystals have been recently suggested to involve the activation of 
the NLRP3 inflammasome and IL-1β [58]. The role of this cytokine in the pathogenesis of 
inflammation in gout has been strengthened by studies showing that the biologic Anakira 
(recombinant IL-1Ra) has beneficial therapeutic effects in gout [59,60]. However, in the literature 
the role of other specific inflammatory components necessary for gouty onset as such as IL-16, 
TREM-1, JE, Rantes and SDF-1 that we found up-regulated and modulated in MSU crystals-and 
IL-17Ab-treated mice respectively, is less clear. In this context the presence of IL-17 could justify 
the overproduction of these soluble mediators released from activated monocytes/macrophage in the 
later stage of gouty inflammation. In fact, an aspect that should not be omitted is that the presence 
of IL-17, at the later stages of an inflammatory response, has been proposed to be the main 
contributor to chronic inflammation due its ability to sustain the recruitment of neutrophils and 
inflammatory monocytes [61,62], mainly by the selective production of JE, IL-16 and TREM-1 
[23,24,25,63]. Given that this cytokine is thought to contribute to the pathogenesis of this disease, 
targeting the IL-17 axis could represent an attractive option for inflammatory-related diseases.  
IL-16 and TREM-1 are classically considered key players in rheumatoid arthritis and inflammatory-
related diseases due their ability to modulate neutrophil migration across the epithelium [64] and 
macrophage infiltration at pathological sites [65,66]. Recent studies also demonstrated that 
fibroblast-like synoviocytes from RA patients express higher levels of IL-16 compared to those 
from osteoarthritis patients [67] and that TREM-1 is involved in both neutrophil migration and 
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macrophage infiltration in chronic inflammatory pathologies [64,68] thus providing a possible 
explanation for the amplified inflammatory response we observed in our study. 
Considering this scenario, it makes sense that patients with RA display high level of IL-17 and are 
more sensitive to an anti-IL-17 inhibitor. Accordingly, in most of these patients, anti-IL-17 
treatment leads to the reduction of symptoms, inflammation and bone destruction [69,70]. 
Moreover, it should be noted that IL-17 has been shown to play a key role in other forms of 
arthritis, such as Psoriatic Arthritis (PsA), in which the induction of IL-17 cytokines axis (IL-17A, 
IL-17F and IL-22) promotes intra-and/or peri-articular inflammation [71,72,73]. To better 
understand this previous observation and viewing the coin from other side a flow cytometry 
bioassay was carried out on peripheral blood to evaluate the balance Treg/Th17 after MSU crystals 
induction and IL-17Ab treatment. Interestingly, our results show that IL-17Ab selectively reverted 
Th17 systemic positive cells “normally” up-regulated after MSU crystals injection, without 
interfering with Treg population. 
 
5. Conclusion 
Overall, our findings and previously reported evidences suggest that IL-17 may play a crucial role 
in the joint pathology at the late phase of crystal-induced acute inflammation/arthritis. What we 
think as most interesting and novel in this study is the possibility of the existence of two 
mechanisms of inflammatory amplification during gouty inflammation: one local and the second 
systemic that in turn amplify and sustain the inflammatory onset but, intriguingly, both related to 
Th17 and IL-17 biology. Future elucidation of the pathophysiological roles of IL-17 in gouty 
inflammation will be crucial in the understanding the precise mechanism of crystal-induced 
inflammation and will possibly provide a new strategy for the treatment of this pathology. 
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